MedTrace Logo

Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

NCT02808091 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-09-05

No results posted yet for this study

Summary

* Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage III - IV.
* Assess the toxicity and maximum tolerated dose of bortezomib administered in combination with GIFOX chemotherapy.

Conditions

  • Extranodal NK-T-CELL LYMPHOMA

Interventions

DRUG

GIFOX-Bortezomib

GIFOX-Bortezomib will be given every 21 days for 4 cycles

DRUG

GIFOX-Bortezomib

GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.

RADIATION

IMRT

a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Soon Thye LIM · National Cancer Centre, Singapore

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-11-30
Completion
2014-03-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02808091 on ClinicalTrials.gov